Trial Profile
Safety and efficacy of Abatacept in patients with treatment-resistant sarcoidosis - ABASARC
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Jul 2022
Price :
$35
*
At a glance
- Drugs Abatacept (Primary)
- Indications Pulmonary sarcoidosis
- Focus Therapeutic Use
- Acronyms ABASARC
- 21 Apr 2021 Status changed from active, no longer recruiting to completed.
- 24 Feb 2020 Status changed from recruiting to active, no longer recruiting.
- 27 Aug 2018 Status changed from not yet recruiting to recruiting.